Hongkou Capital

Day Zero Diagnostics Inc. is an innovative company focused on transforming infectious disease diagnostics through advanced sequencing technologies. Based in Boston, Massachusetts, the company has developed a rapid diagnostic system that identifies bacterial species and their antibiotic resistance profiles directly from clinical samples. Key technologies include Blood2Bac, which enriches bacterial DNA, and BacDetect, allowing for swift detection of bacterial DNA. Additionally, the company employs machine learning algorithms for genomic antibiotic susceptibility testing and maintains a comprehensive microbial database that integrates genomic sequencing data with resistance profiles. By enabling rapid and accurate diagnoses, Day Zero Diagnostics aims to address critical needs in managing bloodstream infections and sepsis, reducing the time for diagnosis from days to hours and improving patient outcomes through targeted treatments.

Amionx develops Safe Core technology that functions as a circuit breaker within lithium‑ion batteries, preventing fires and explosions without compromising performance. The system protects against overcharge, internal short circuits, and external heat across all battery chemistries, including solid‑state designs. By integrating safety at the core of the battery, Amionx enables original equipment manufacturers to reduce battery‑related accidents and enhance overall reliability.